Mitsuhiro Fukata
Overview
Explore the profile of Mitsuhiro Fukata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moriyama S, Kondo M, Awamura R, Hieda M, Fukata M
Circ Rep
. 2025 Feb;
7(2):59-65.
PMID: 39931708
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy often lead to severe sarcopenia and cachexia during treatment, making it difficult to maintain exercise tolerance. Consequently,...
2.
Hamasaki H, Arimura H, Yamasaki Y, Yamamoto T, Fukata M, Matoba T, et al.
Phys Eng Sci Med
. 2024 Dec;
PMID: 39739189
This study proposed noninvasive machine-learning models for the detection of lesion-specific ischemia (LSI) in patients with stable angina with intermediate stenosis severity based on coronary computed tomography (CT) angiography. This...
3.
Furukawa K, Ohmura H, Moriyama S, Uehara K, Ito M, Tsuchihashi K, et al.
Jpn J Clin Oncol
. 2024 Oct;
55(2):113-122.
PMID: 39385509
Background: Malignant primary cardiac tumors require multimodal approaches including surgery, chemotherapy and radiotherapy, but these treatments can be associated with cardiovascular complications. However, few reports have described the cardiovascular complications...
4.
Kondo M, Nakamura Y, Kato Y, Nishimura A, Fukata M, Moriyama S, et al.
J Pharmacol Sci
. 2024 Aug;
156(2):69-76.
PMID: 39179336
Despite the widespread recognition of the global concern regarding the onset of cardiovascular diseases in a significant number of patients following cancer treatment, definitive strategies for prevention and treatment remain...
5.
Hatakeyama K, Kikushige Y, Ishihara D, Yamamoto S, Kawano G, Tochigi T, et al.
Blood Adv
. 2024 Jan;
8(3):785-796.
PMID: 38163319
Immunomodulatory drugs (IMiDs) are key drugs for treating multiple myeloma and myelodysplastic syndrome with chromosome 5q deletion. IMiDs exert their pleiotropic effects through the interaction between cell-specific substrates and cereblon,...
6.
Futami S, Hieda M, Fukata M, Shiose A
Eur Heart J Case Rep
. 2023 Aug;
7(8):ytad331.
PMID: 37547377
Background: Cystic myxomas are quite rare. Moreover, few reports have evaluated the causes that constituted them. Case Summary: A 73-year-old Asian man presented for pre-operative examination of osteoarthritis, and transthoracic...
7.
Sato T, Hieda M, Futami S, Fukata M, Shiose A
Eur Heart J Case Rep
. 2023 Feb;
7(1):ytad025.
PMID: 36727124
Left ventricular assist device (LVAD) is essential for patients with severe heart failure, but there is a risk of thrombus formation on the aortic root and cusps, leading to coronary...
8.
Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy
Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, et al.
Open Heart
. 2023 Jan;
9(2).
PMID: 36600585
Background: Cancer treatment with vascular endothelial growth factor signalling pathway (VSP) inhibitors frequently causes hypertension. Although previous reports suggested that the antihypertensive drug renin-angiotensin system inhibitor (RASI) may have a...
9.
Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, et al.
Circ J
. 2022 Dec;
88(2):217-225.
PMID: 36476830
Background: Hypertension is a frequent adverse event caused by vascular endothelial growth factor signaling pathway (VSP) inhibitors. However, the impact of hypertension on clinical outcomes during VSP inhibitor therapy remains...
10.
Mawatari S, Fukata M, Arita T, Maruyama T, Kono S, Fujino T
Brain Res Bull
. 2022 Aug;
189:5-10.
PMID: 35973579
Decreased plasma levels of plasmalogens in neurodegenerative diseases have been watched with interest. We previously reported the decreases of erythrocyte ethanolamine plasmalogen (PlsPE) of blood not only in Alzheimer's disease...